Our mission is to harness the power of the immune system to bring curative therapies to cancer patients

Listen to the Agenus
Biotech 2050 Podcast

Leadership in Revolutionizing Cancer Immunotherapy.

Spotlight on botensilimab

Agenus’ next-generation CTLA-4 antibody

Botensilimab was designed to:

Extend the curative benefits of I-O to cold tumors that do not respond to approved immunotherapies. This is achieved by optimizing T cell interactions to drive increased potency.
Expand clinical benefit in hot tumors such as melanoma, where CTLA-4 is approved, but reported results show clinical benefit in only a third of patients and long term survival in less than a quarter of patients.
Improve tolerability by reducing or eliminating side effects that cause treatment discontinuation.

Innovation in immunotherapy

What is immunotherapy for cancer?

Today, we can create drugs that empower the immune system to do its job – cure disease.

How does botensilimab work?

By modifying the Fc “tail” of the antibody, our scientists discovered that its efficacy and tolerability can be significantly enhanced.

Why Agenus?

Our diverse portfolio of immunotherapies, vertically integrated capabilities from discovery through manufacturing, and partnerships with industry leaders uniquely position us to adopt a comprehensive approach to discover and develop cancer therapies.

By the numbers

Agenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics), adjuvants and vaccines (through subsidiary SaponiQx).

clinical-stage antibody programs

0 K

US patient opportunity for lead program

$ 0 B

partnership transactions

$ 0 B

annual manufacturing capacity for botensilimab at planned Emeryville site

Acceleration through partnerships

While we retain ownership in the majority of our programs, we have accelerated the development of select programs through partnerships with industry leaders. These partnerships generate capital to further support our pipeline development, and many offer optionality for future participation in development and commercialization.

Who we are

We have brought together top talent and expertise to advance our mission, building a team of over 400 employees across our offices in the US and Europe.

Listen to the Agenus Biotech 2050 Podcast